We put inspiration into practice, finding viable solutions to complex challenges.
Great ideas are our starting point.
Research focus
Der SFB1399 geht in die 2. Förderperiode
Der Sonderforschungsbereich “Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer (SFB1399)" geht in die zweite Runde. Die deutsche Forschungsgemeinschaft (DFG) entschied, dass das von der Universität Köln im Jahr 2019 initiierte Projekt die Förderung für weitere vier Jahre erhält.
We are TRON
TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.
Our Research Focus
TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system. Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.
Target Discovery and Validation
Personalized Therapy Development
Preclinical Vaccine Development
Cellular Therapy Development
Supported by
